mAbxience has established itself as a pillar in the biotechnology industry, with over 14 years of dedicated service in developing and manufacturing biopharmaceuticals that target life-threatening conditions.
Ahead of CDMO Live, we spoke to Silvana Di Cesare, CDMO Director and Alvaro Camino, CDMO Alliance Manager for mAbxience, to understand what makes them a unique contract partner.
“Our track record is marked by significant achievements, such as our partnership with AstraZeneca during the COVID-19 pandemic, where we showcased our ability to meet urgent and large-scale health challenges. This project demonstrated our capacity to execute rapid virtual tech transfers, completing them in just three months, and delivering 240 million vaccine doses in fifteen months. Proof of our operational excellence and commitment to high quality medicines accessible across the globe.” says Silvana.
Operating out of state-of-the-art facilities in Spain and Argentina, mAbxience is equipped with modern, single-use technologies and a consistent setup across sites that ensure both flexibility and control in production processes.
“Our facilities boast a wide range of capabilities, with flexible production scales from 2L to 4000L single-use bioreactors and a total mammalian cell culture capacity reaching 50,000L. This enables us to efficiently scale operations and swiftly adapt to the changing demands of the market and our partners.”
Quality and regulatory compliance are the cornerstones mAbxience’s operations.
“We rigorously adhere to the highest GMP standards, validated by over 20 worldwide GMP certifications from prestigious regulatory bodies including the FDA, EMA, PDMA and TGA. With 15% of our staff dedicated to quality and compliance, we maintain an impressive batch success rate of over 97%. Our meticulous attention to detail ensures that every product manufactured meets the most stringent quality benchmarks, aligning with our mission to deliver affordable and accessible high-quality medicines globally.”
“Our operational strategy is defined by an integrated and lean structure, enhancing both agility and cost-effectiveness. Specialized Material Science and Applied Technology (MSAT) teams at each site ensure rapid and efficient technology transfer, which is crucial for a seamless transition from small-scale runs to commercial-scale production. Additionally, our robust supplier management system supports continuous supply chains, essential for maintaining uninterrupted production lines.”
Patient-centricity
At the core of mAbxience’s operations is a patient-centric approach that emphasizes personalized engagement with our partners.
“We work closely with our clients to tailor our services to their specific needs, ensuring that every project not only meets but exceeds expectations. This collaborative partnership model supports our clients’ goals from the initial stages of development through to launch and beyond, fostering a relationship built on trust, mutual respect, and success.”
As the biopharmaceutical sector continues to evolve, the strategic importance of selecting the right CDMO partner becomes increasingly clear. mAbxience, with its comprehensive suite of services, expert team, and proven track record, is ideally positioned to assist biopharmaceutical companies in navigating the complexities of drug clinical development and market access.
For those in the biopharmaceutical field looking to accelerate the development and commercialization of their products, mAbxience offers the expertise, innovation, and reliability needed to transform drug discovery concepts into tangible, life-saving treatments.
Reach out to mAbxience at co*****@*******ce.com to explore how our CDMO solutions can support your manufacturing needs and help advance global healthcare.
Let’s begin the journey to a healthier tomorrow together.
